Royalty Report: Drugs, Cancer, Therapeutic – Collection: 335861


Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 3


This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 3

Primary Industries

  • Drugs
  • Cancer
  • Therapeutic
  • Biotechnology

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 335861

License Grant
Licensor hereby grants to Licensee an exclusive, royalty-bearing right and license, in the Field in the Territory, including the right to grant sublicenses, to make, have made, use, develop, commercialize, offer for sale, have sold, and import Licensed Products.
License Property
This intellectual property relates to intratumoral administration of a combination of a chemotherapeutic agent and an immunomodulatory agent for cancer therapy ( “Cancer Therapy IP”). The concept of the Cancer Therapy IP is the simultaneous intratumoral injection of a chemotherapeutic agents in combination with immunomodulatory agents in sustained release formulations. The chemotherapeutic agent is for the purpose of directly killing the tumor cells for the release of antigens while the immunomodulatory protein or factor is to stimulate the antigenic response of the host to the antigens.

U.S. Provisional Application No. 63/120,673 – Cancer Therapy by Intratumoral Injection of a Chemotherapeutic Agent compination with a Bioactive Immunostimulatory Agent.

License IP means Cancer Therapy by Intratumoral Injection of a Chemotherapeutic Agent combination with a Bioactive Immunostimulatory Agent.

Field of Use
Field shall mean all therapeutic uses related to treatment of diseases in humans.  The Licensee has expertise in the field of oncology.

IPSCIO Record ID: 26619

License Grant
The Licensor hereby grants to the Licensee and its Affiliates a sole and exclusive worldwide sublicense in all fields of use to practice under the Patent Rights and to utilize the Know-how, and to make, have made, use, lease and/or sell the Licensed Products and to practice the Licensed Processes, to the full end of the term for which the Patent Rights are granted, unless sooner terminated as hereinafter provided.
License Property
The Licensor desires to sublicense of such Patent Rights and Know-how in order to commercialize 06-Benzyl guanine (06BG) and related technologies for the treatment of cancer.

O6-Benzylguanine (O6-BG) is a chemosensitizer that is designed to overcome resistance to a significant class of commonly used chemotherapeutic agents known as O6-alkylating agents.  In preclinical animal studies, treatment with O6-BG increased the anti-tumor activity of these agents in brain, colon, and prostate cancers, as well as in melanoma.   A Phase II development program began in 1999.  O6-BG, a series of related compounds and a gene therapy that the Company believes will enhance the effectiveness of a class of currently used chemotherapeutic agents known as O6-alkylating agents.  O6-BG and related compounds are small molecules for intravenous administration in the treatment of cancer.  The Company believes O6-BG to be capable of destroying the resistance of cancer cells to a class of chemotherapeutic agents, O6-alkylating agents.  The Company believes that the effectiveness of alkylating chemotherapeutic agents against various tumors such as brain, prostate, colon cancers, melanoma and lymphoma is limited due to the ability of tumor cells to repair the DNA damage caused by the O6-alkylating agents, because the DNA repair protein, O6-alkylguanine-DNA alkyltransferase (AGT), protects tumor cells by repairing the tumor cell DNA.

The Company believes that O6-BG inactivates the AGT protein in a variety of cancers thereby overcoming resistance to theO6-alkylating agents.

Field of Use
The rights granted apply in all fields of use relating to technologies for the treatment of cancer.

IPSCIO Record ID: 245947

License Grant
The Foundation, not-for-profit academic medical center,  hereby grants to Licensee an exclusive license under the Licensed Rights to (a) make, have made, develop, use, import, export, distribute, market, promote, offer for sale and sell Products, (b) practice any method, process or procedure within the Licensed Patents or the Foundation Technology, and (c) otherwise exploit the Licensed Rights within the Licensed Territory for use within the Licensed Field; and to have any of the foregoing performed on its behalf by a third party.   The Parties have consented to the licensing of the Invention and Patent Rights under the License Agreement as amended by the terms set forth.
License Property
Patent Rights means all right, title and interest of the parties in, to and under any of the following
US Patent Number / Application    60/571,149
MDR Inhibitors which are the subject of the Patent Rights ('Invention').

Panacela Product shall mean the following Products developed and commercialized by Panacella
(i)   Arkil small-molecular polycyclic organic compound for systemic use to treat hormone-independent prostate tumors;
(ii)  Mobilan recombinant adenovirus of CBLB501 series for localized intratumor injection, converts the injected tumor into an efficient vaccine in situ by intratumor expression of a bacterial immunogen and its receptor; and

(iii)  Revercom nano-particle combining a chemotherapeutic drug with an inhibitor of the tumor drug resistance molecular mechanism of CBLC500 series for the treatment of tumors resistant to chemotherapy.

Foundation Technology shall mean all Foundation’s and Other Institution’s unpatented inventions, know-how, trade secrets, analysis, discoveries, techniques, methods, clinical and other data, and other intellectual property relating to the research of Doctor or arising out of or in direct connection with work of Doctor in the field of regulating cell death (i) curing cancer treatment side effects by differential modulation cell death / survival mechanisms uniquely deregulated in cancer cells; (ii) selective sensitization of cancer cells to treatment by using the same approach; (iii) using anti-apoptotic proteins secreted by microbial parasites to cure tissue damage associated with cancer treatment, inflammation and other pathologies (stroke, heart attack).

Field of Use
The Licensed Field means 0500 series modulating the androgen receptor (AR) pathway, constant activity of which is essential for growth and viability of the majority of prostate cancers, including those that have lost their dependence on androgen.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.